RECLAIM
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 34 patients (estimated)
- Sponsors
- Medical College of Wisconsin
- Tags
- Bispecific Antibody, Bispecific T Cell Engager (BiTE), B-Cell Maturation Antigen (BCMA), CD3, Post-CAR T
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2137
- NCT Identifier
- NCT07009899
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.